<DOC>
	<DOCNO>NCT01883648</DOCNO>
	<brief_summary>This randomize , cross study determine efficacy coconut oil subject mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Study Evaluate Coconut Oil Alzheimer 's Disease</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , cross study determine efficacy coconut oil ( proprietary blend coconut medium chain triglyceride oil , administer orally three time daily ) subject Alzheimer 's disease screen ApoE 4 allele . The study medication formula Cognate Nutritionals Fuel Thought™ . Approximately 65 subject treat coconut oil beverage ( Fuel Thought™ ) placebo three month , give 3-5 day interim wash period . After , subject resume three month treatment opposite treatment arm . Total treatment period 6 month .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Men woman age 55 90 year diagnosis mild moderate Alzheimer 's disease Informed consent sign date subject ( legally authorize representative ) . Subjects must study partner must also consent participate study , spend least 10 hours/week study . The study partner must attend applicable clinic visit provide information subject . Subject must screen MiniMental State Examination score 1626 . Subjects must Rosen Modified Hachinski Ischemic score ≤4 . Subject must undergo ApoE genetic laboratory test baseline visit . Subject must willing able take study medication ( placebo ) duration study . Subject must stable memory enhance medication include cholinesterase inhibitor ( include donepezil , rivastigmine , galantamine ) NMDA antagonist ( memantine ) least 3 month prior screen agree change medication course participation , unless medically necessary . Subject must stable memory enhance nonprescription supplement ( include gingko biloba , huperzine , resveratrol , docosahexaenoic acid ) least 3 month prior screen agree change medication course participation . As judged Investigator , subject study partner compliant high probability complete study , include schedule evaluation require test . Be fluent English . Has significant neurological medical disease , AD , may affect cognition , example , history evidence hydrocephalus , uncontrolled hypo hyperthyroidism . Current , clinically significant major psychiatric disorder ( eg , major depressive disorder ) accord Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) , symptom ( eg , hallucination ) could affect subject 's ability complete study . Geriatric depression scale score 6 suicidal ideation . Current clinically significant chronic illness likely result deterioration subject 's condition affect subject 's safety study , include uncontrolled diabetes . Subjects history diabetic ketoacidosis also exclude . Other case diabetes decide discretion study physician . Subjects diabetes control exercise diet may screen admission study depend screen safety laboratory assessment . History clinically evident stroke history clinically significant carotid vertebrobasilar stenosis plaque risk factor thromboembolic stroke ( e.g atrial fibrillation , clinically significant low ventricular output , atrial septal defect ) . History seizure . Clinically significant infection within last 30 day ( eg , chronic persistent acute infection [ eg , upper respiratory infection , urinary tract infection ] ) , prior screen . Myocardial infarction within last 2 year . Abnormal screen visit electrocardiogram ( ECG ) , opinion investigator . Uncontrolled hypertension within last 6 month prior screen . History cancer within last 3 year , exception nonmetastatic basal cell carcinoma squamous cell carcinoma skin . ( Note : cancer must remission sign progression . ) Use experimental investigational medications/devices treatment within 90 day prior screen . Laboratory finding fast total cholesterol great equal 240 mg/dL Laboratory finding fast triglyceride great equal 200 mg/dL Laboratory finding fast glucose great equal 126 mg/dL Other clinically significant abnormality physical , neurological , laboratory , vital sign , ECG examination ( eg , change consistent recent infarction , ischemia , clinically significant arrhythmia clinically significant conduction defect ) could detrimental subject compromise study . Does adequate venous access would allow blood draw . Subject study partner relate study personnel . Subjects take coconut oil supplement within last 30 day . Subjects take Axona™ within last 30 day . Women pregnant . ( Women child bear potential must take precaution become pregnant study . )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Mild Moderate Alzheimer 's disease</keyword>
</DOC>